Reevaluating immunization delays after red blood cell transfusion

Area of Science:

• Pediatrics
• Immunology
• Hematology

Background:

• Current guidelines recommend delaying live vaccines like MMR by 5-6 months post-RBC transfusion.
• These recommendations, based on limited data, may hinder timely vaccination for children needing frequent transfusions.
• This study investigates MMR vaccine immunogenicity in chronically transfused pediatric patients.

Purpose of the Study:

• To assess measles, mumps, rubella (MMR) vaccine immunogenicity in pediatric patients receiving chronic red blood cell (RBC) transfusions.
• To quantify MMR vaccine antibodies present in RBC donations.

Main Methods:

• Quantified MMR-specific antibodies in 25 pediatric patients post-vaccination while on chronic RBC transfusion.
• Analyzed MMR antibodies in supernatants from 30 RBC donations.
• Compared antibody levels with vaccination dates and blood donor birth years.

Main Results:

• Measles, mumps, and rubella vaccine immunity ranged from 68% to 76% in transfused patients.
• Pre-1976 blood donors (pre-MMR vaccine era) showed higher MMR antibody levels (67%) in donations compared to post-1976 donors (7%).
• MMR antibody levels in RBC donations appear to decrease over time.

Conclusions:

• This is the first study demonstrating MMR vaccine immunogenicity in chronically transfused patients.
• Despite lower rates than general populations, MMR vaccine immunogenicity is significant in this cohort.
• Re-evaluation of current immunization delay guidelines after RBC transfusions is warranted to optimize disease prevention in vulnerable children.